The issue price of 557.8 yuan, the most expensive new share in the history of a shares, Hemai shares, attracted much attention. The issuance results were released and the purchase of 363 million yuan, which was rare in history, was abandoned.
The myth of invincibility of A-share new shares is constantly being broken. After winning the lottery, some investors may also give up or forget to pay. This is another large amount of abandonment after Baiji Shenzhou abandoned its purchase of 199 million.
highest priced new shares in history
securities companies rarely underwrite 363 million
On December 14, Hemai shares disclosed the IPO results of a shares, and 651387 shares were abandoned. Based on 500 shares signed, about 1302 online investors did not pay after winning the lot, and the amount of abandoned purchase was RMB 363 million.
The purchase abandonment of RMB 363 million was finally underwritten by the lead underwriter Citic Securities Company Limited(600030) ; The proportion of the number of underwritten shares in the number of shares issued this time after deducting the final strategic placement is 7.0307%, and the proportion of the number of underwritten shares in the total scale of this issuance is 6.5139%.
In addition, as a sponsor (lead underwriter) Citic Securities Company Limited(600030) , its alternative investment wholly-owned subsidiary Citic Securities Company Limited(600030) also participated in the follow-up investment of Hemai shares, with 200000 shares, an amount of RMB 116 million and a sales restriction period of 24 months.
Equivalent to Citic Securities Company Limited(600030) buying Hemai shares for 481 million yuan, nearly 500 million!
Of course, Hemai shares issued 10 million shares and raised 5.578 billion yuan; Citic Securities Company Limited(600030) the sponsor underwriting fee is also a lot, 141.5 million yuan.
However, Citic Securities Company Limited(600030) will also be damaged in case of a large break in the listing of Hemai shares.
in case of signing in recent 28 days, some investors may worry about
The reason why Hemai shares were so abandoned is considered to be related to the high issue price. The issue price of the shares is 557.8 yuan, and 278900 yuan needs to be paid as soon as 500 shares are signed.
The absolute amount of winning a lot is large. For ordinary investors, if the listing breaks down by 10%, they will lose 2789 yuan. Moreover, from the simple price earnings ratio valuation, the valuation of Hemai shares is not low.
Hemai Co., Ltd. is a high-tech enterprise mainly engaged in photovoltaic inverter and other power conversion equipment and complete electrical equipment. The company's products include micro inverter and monitoring equipment, as well as modular inverter and other power conversion equipment designed according to the concept of micro inverter.
In terms of performance, from January to September 2021, Hemai shares realized an operating revenue of 507 million yuan, a year-on-year increase of about 65.94%, a net profit attributable to shareholders of the parent company of 121.6016 million yuan, a year-on-year increase of 85.99%, and a net profit of 117.8676 million yuan after deduction, a year-on-year increase of 90.51%. It is estimated that the net profit attributable to the shareholders of the parent company in 2021 will be RMB 180 million to RMB 210 million, with a year-on-year increase of about 73% to 102%; It is estimated that the net profit after deducting non-profit is RMB 175 million to RMB 205 million, with a year-on-year increase of about 77% to 108%.
The issue price of 557.8 yuan corresponds to 225.94 times the issue price earnings ratio of Hemai shares, and the market value of the company corresponding to the issue price is 22.3 billion yuan.
new shares are frequently broken
there was a contract loss of 15000
Recently, the frequent breaking of new shares may make investors worried about the listing of Hemai shares. Jiahe Meikang (n Jiahe), which was listed on December 14, broke once, and Dizhe medicine, which was listed on December 10, broke more than 20% on the day of listing.
For Liaoning Chengda Biotechnology Co.Ltd(688739) listed at the end of October, the issue price of 110 yuan fell to 80 yuan on the same day. Once signed, it would lose 15000 yuan, and the latest share price is still lower than 80 yuan.
(China Fund News)
